Association Between Exposure to Per- and Polyfluoroalkyl Substances and Birth Outcomes: A Systematic Review and Meta-Analysis

Si-Yu Gui, Yue-Nan Chen, Ke-Jia Wu, Wen Liu, Wen-Jing Wang, Huan-Ru Liang, Zheng-Xuan Jiang, Ze-Lian Li and Cheng-Yang Hu

Background: A large body of emerging evidence suggests that per- and polyfluoroalkyl substances (PFAS) affect birth outcomes in various pathways, but the evidence is inconsistent. Therefore, this study aimed to systematically review the epidemiological evidence on PFAS exposure and birth outcomes.

Methods: Three electronic databases were searched for epidemiological studies through February 13, 2021. We used random-effects meta-analysis for eight birth outcome indicators to calculate summary effect estimates for various exposure types. The risk of bias and the overall quality and level of evidence for each exposure-outcome pair were assessed.

Results: The initial search identified 58 potentially eligible studies, of which 46 were ultimately included. Many PFAS were found to have previously unrecognized statistically significant associations with birth outcomes. Specifically, birth weight (BW) was associated with PFAS, with effect sizes ranging from $-181.209 \text{ g}$ (95% confidence interval (CI) = $-360.620 \text{ to } -1.798$) per 1 ng/ml increase in perfluoroheptanesulfonate (PFHpS) to $-24.252 \text{ g}$ (95% CI = $-38.574 \text{ to } -9.930$) per 1 ln (ng/ml) increase in perfluorodecanoic acid (PFDA). Similar patterns were observed between other PFAS and birth outcomes: perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with birth length (BL) and ponderal index (PI), PFOS and perfluorododecanoic acid (PFDoDA) with head circumference (HC), PFHpS with gestational age (GA), and perfluorononanoic acid (PFNA) and PFHpS with preterm birth (PTB). Additionally, PFDA showed a statistically significant association with small for gestational age (SGA). The level of the combined evidence for each exposure-outcome pair was considered to be “moderate”.

Conclusion: This study showed that PFAS exposure was significantly associated with increased risks of various adverse birth outcomes and that different birth outcome...
INTRODUCTION

Per- and polyfluoroalkyl substances (PFAS) have become one of the most widely investigated classes of persistent organohalogen compounds of environmental concern. They have been used for a multitude of industrial and consumer-use products, including fire-extinguishing foams, photographic emulsifiers, furniture, carpets, leather, and paper (1–3). PFAS include a cluster of substances that are classified as persistent organic pollutants due to their high resistance to biodegradation, hydrolysis, and atmospheric photo-oxidation (4); the reason for their remarkable stability is because their F-C (fluorine–carbon) covalent bond is stronger than H-C (hydrogen–carbon) bonds (5). These substances are widespread in global ecosystems and even in wildlife in the Arctic, where direct exposure to synthetic chemicals is rare. Therefore, it is unsurprising that, according to biomonitoring data, the general population has had extensive exposure to certain PFAS that are persistent in the environment and capable of bioaccumulation in the food chain (6). Worse, some of these PFAS are transferred through the placenta (7). Thus, PFAS are becoming increasingly significant for the international community in terms of ecological and environmental impacts and human health hazards (4, 8, 9), not only because they are widely used in households but also because the shorter-chain PFAS accumulated in wildlife and humans still have a continuous widespread effect on the environment (10, 11).

The World Health Organization (WHO) estimated that children under 5 years of age bear more than 40% of the burden of environment-related diseases despite accounting for only 10% of the global population (12–14). Air pollution has been extensively studied as a direct cause of child health problems, such as adverse birth outcomes, impaired cognitive and behavioral development (15–17), and respiratory diseases (18, 19). Additionally, environmental exposures, including prenatal exposure to metals, organochlorine pesticides, and other persistent organic pollutants (POPs), have been reported to be associated with adverse birth outcomes (4, 20, 21), including PTB, low birth weight (LBW), SGA, and other birth anthropometric features (BW, HC, and BL). Therefore, clarifying the relationship of environmental exposures, especially exposures to persistent compounds, with birth outcomes is a task of considerable significance to public health (3, 13, 20).

The detrimental effects of PFAS have attracted great attention over the past few years. Many reports have shown that PFAS exposure is associated with cancer risk (22), immune function (23), reproductive function (24), renal function (25), endocrine function (26, 27), and the risk of metabolic diseases (28). The U.S. EPA (Environmental Protection Agency) has reported that PFOA may cause human cancer (15), and some other PFAS are listed under the Stockholm Convention for global regulatory action (29–31). In addition, both animal and human studies have shown that PFOS and PFOA may negatively impact birth outcomes (13, 30, 32). Recent studies have indicated that PFAS may influence human sex hormone biosynthesis, serum levels, and receptors (33–35). However, the specific mechanism involved remains largely unknown. Since 2007, the number of relevant studies per year has steadily increased; most of these studies have focused on the associations of PFOS or PFOA with BW (20, 36–38). Additionally, the number of studies on long-chain PFAS exposure and fetal growth indicators is much less than that of well-known short-chain PFAS (e.g., PFOA/PFOS). In addition, some studies (39–41) revealed that differences in fetal sex and gestational order may influence the exposure and birth outcome associations, while others (12, 29, 42–45) discussed the time-course variation in the timing of PFAS collection vs. exposure measurement. Although some epidemiological studies have been conducted to explore the associations, the conclusions of this evidence are quite inconsistent or even opposite (12, 13, 20, 38, 46, 47), even if studies (48, 49) focus on only one outcome indicator (e.g., BW). Such inconsistency may be related to the degree of adjustment for confounding factors, the difference in study design and population characteristics, and the difference in ways of data units and transformations. These inconsistencies make it difficult to interpret the results and then provide specific advice to policy-makers. Therefore, it is necessary to synthesize and evaluate this evidence from multiple sources.

In the massive body of available environmental epidemiological research regarding the effects of PFAS on human health, systematic reviews and meta-analyses (SRMAs) are increasingly used to quantitatively combine data across studies and help translate evidence into policies. However, as massive data available on the effects of PFAS on human health, few studies have investigated the relationships of specific exposure and outcome combinations. To our knowledge, only one SRMA has assessed the effects of PFAS exposure on pregnancy outcomes including miscarriage, PTB, and stillbirth, and four meta-analyses focused on PFOA/PFOS with BW. Specifically, the SRMA (50) on pregnancy outcomes encountered a crucial methodological issue in which estimates from single studies are not comparable and thus make the final estimates difficult to interpret. In the three studies on BW (47, 48, 51), they all concluded that PFOA was significantly associated with BW. Regrettably, Johnson et al. (51) did not distinguish samples originating from plasma vs. serum and did not fully incorporate the available data (only 1 ng/ml increments of PFOA were included). Similarly, Negri et al. (47) and Steenland et al.
highlighted differences in the shape of the dose-response curves and presented their data in both forms of analyses (per ng/ml and ln ng/ml). Most recently, one review (52) examined the association of PFAS exposure with the risk of PTB in the United States and suggested that PFAS exposure was a “significantly associated” risk of PTB.

In addition to the aforementioned deficiencies, these four studies also failed to analyze other types of PFAS (particularly, few long-chain PFAS in place of short-chain PFAS have been reported) and more types of birth outcome indicators. Furthermore, only a small fraction of studies noted differences in exposure distribution characteristics (or forms of data transformation) (log-transformed vs. non-log-transformed) and sample collection effects of timing and type, not to mention further meta-analyses for gender and other subgroups. Therefore, there is an increasingly urgent need for systematic reviews and meta-analyses on the relationships between different types of PFAS and different birth outcome indicators in a more rigorous and standardized format as well as for detailed studies of heterogeneity and assessment of the quality of evidence.

In this sense, our study aimed to further clarify the existing inconsistent findings and summarize the latest evidence in a more standardized and detailed format. It is supposed to provide policy-makers and health care providers with a more comprehensive assessment of the association between PFAS and birth outcomes, thereby improving the preventive health of the public, especially for pregnant women.

**METHODS**

**Search Strategy**

Our reporting process is based on the PRISMA Statement Guidelines (53) (Supplementary Table 1). Primarily, following the PECOS (Population, Exposure, Comparator, Outcome, Study) statement, we configured the following as the specific research question: “Among pregnant women exposed to perfluorinated compounds (population), when exposed to or present with one or more perfluorinated compounds in the body (exposure), are they linked with worse birth outcomes (outcome) than those who are assessed to have a low risk of exposure to perfluorinated compounds or who have the lowest level of concentration in body (comparator) evaluated in all (study design)?” Studies were identified through a bibliographic search in Web of Science, PubMed, and EMBASE databases. Search terms (perfluoride OR perfluorinated OR perfluorooalkyl OR pfc OR pfc5 OR PFASs OR fluoride OR fluorides OR fluorinated OR fluoride OR polyfluorinated OR pfluor ox OR pfluorpa OR pfoa OR pfoa OR pfoa OR pflua OR pfluda OR pfluda OR pfluda OR pfluorina OR pfluorins OR PFHxs OR pfos OR mepfosa OR mepfosa OR etfosa OR pfa) and (birth outcomes OR adverse birth outcomes OR birth weight OR low birth weight OR preterm birth OR gestational age OR small for gestational age) were used to identify eligible studies. The search is not limited by languages with the last update on February 13, 2021. Supplementary Table 2 shows the detailed search methods and results. Reference lists of the eligible studies and excluded reviews were searched out and deleted.

**Study Selection**

We established the following eligibility criteria according to the predefined PECOS statement: (P): Pregnant women exposed to perfluorinated compounds (living, residing, working or schooling in factories, near polluted water or in polluted environment, etc.); (E): Exposure to or presence of one or more perfluorinated compounds in the body (body fluids such as serum, plasma, etc.) included but not limited to the following categories: “PFCA” OR “PFCS” OR “PFASs” OR “PFAS” OR “PFPeA” OR “PFHxA” OR “PFHpA” OR “PFDoA” OR “PFUnDA” OR “PFDoDA” OR “PFTrDA” OR “PFBS” OR “PFHxS” OR “PFOS” OR “MeFOSAA” OR “EtFOSAA”; (C): People who are assessed to be at low exposure risk to perfluorinated compounds or who are in the lowest level of concentration based on body fluid measurements; (O): Birth outcomes determined by clinical assessments from the International Classification of Diseases (ICD), registry data, or medical records, and here our focus is on BW, BW-Z score, BW/GA-Z score, BL, HC and PI, GA, PTB, LBW and SGA. (S): All cross-sectional, case-control, or cohort studies were considered eligible for the review. First, two coauthors (S.Y.G. and Y.N.C) independently filtered complete titles and abstracts after deleting duplicates. After the initial screening, we downloaded the full text and screened the text again to check whether it could be fully evaluated. All disagreements will be resolved through group discussion.

**Data Extraction and Quality Assessment**

Two authors (S.Y.G. and Y.N.C) independently extracted data using a predefined data template. We defined two sets of studies based on our definition of outcomes. Our main analysis focused on the combined association between different types of PFAS and a variety of indicators for the abovementioned birth outcomes. Details of the extracted eligible studies are shown in Supplementary Table 10. Furthermore, if the necessary information could not be extracted from an article or its Supplementary Materials or related publications, the corresponding author or first author of the selected study was contacted. Meanwhile, for documents that miss the necessary information or that fail to provide necessary data in their Supplementary Materials or relevant publications, we performed a separate image data extraction (ORIGIN software) or contacted their corresponding first author. Then, to assess the quality of each study, we used the correction list used in the study of Andersen, Andreassen, and Krogh (54). The list differentiates high quality from medium and low quality (quality scores from 1.00 to 0.80, 0.79 to 0.60, and <0.60, respectively). Each element has a maximum score of 1.00 and a minimum score of 0.12, and it is then divided into a total score for all elements to calculate a unit-weighted mass score (Supplementary Table 3).

**Risk-of-Bias Assessment**

To confirm the conclusions, we assessed the risk of bias (RoB) for each study included in the meta-analysis. RoB assessment describes the quality of research and may indicate systematic errors in results associated with methodological quality assessments (55). For each study, classification was performed...
across human and animal studies using the NTP/OHAT risk of bias tool (56). In the observational studies, three important factors (detection bias, confounding bias in exposure and outcome assessment) and four other factors (selection bias, consumption/exclusion bias, selective reporting bias, and conflict of interest) were taken into account. A series of questions were used to evaluate the risk for each item as “absolutely low,” “possibly lower,” “possibly higher,” or “absolutely high.” (see Supplementary Table 4 for detailed questions and Supplementary Table 5 for the rationale for evaluations of each included study). The directed acyclic graph (DAG) (A and B) described by Bach et al. (57) portrays the most reliable causal network connecting exposure (PFAS), outcomes (A illustrating the BW, the BL and HC at birth; B illustrating the PTB and the continuous GA outcome), and potential confounders and mediators for the same research topic. As for the confounder bias domain, this domain was assigned a high RoB if the study considered no significant confounders or only one (parity or maternal age or maternal education) was considered; the domain was classified as probably high RoB if at least two of the following confounders (parity or maternal age or maternal education or infant sex or multiple pregnancy or fetal growth or maternal smoking or GA at birth) were considered; the domain was categorized as possibly low RoB if all of the above confounders and maternal pre-pregnancy BMI were considered; the domain was categorized as definitely low RoB if all of the above confounders and at least one of the following confounders was considered: ethnicity, marital status/single motherhood, obstetric history, air pollution/noise, rural vs. urban residence, and green space in the community of residence. The domain was designated as probably high RoB if no sufficient information was available to determine the RoB. Finally, each study was categorized into an overall tier 1, 2, or 3 RoB. RoB assessment was then re-evaluated by two authors and any discrepancies were discussed to reach a consensus.

**Meta-Analysis**

This study was designed to appropriately integrate and analyze the results of individual trials to quantitatively assess the association of exposure to PFAS and birth outcome. We defined 2 exposure-outcome pairs as the threshold for running a meta-analysis, as previous similar studies indicated (58, 59). We considered the study as a cohort (or nested case-control) study if pregnant women were enrolled before the measurement of outcomes (i.e., before delivery) or as a cross-sectional design if women were enrolled at the time of delivery and measured the exposure and outcome concomitantly.

Meta-analyses calculated two types of summary effect estimates: (a) estimate per 1 ng/ml or ln (ng/ml) unit change and (b) estimates at the highest vs. the lowest exposure levels. We performed continuous and categorical exposure meta-analyses because there is no consensus that the association between PFAS exposure and birth outcome is linear or non-linear.

For continuous exposures, we considered their linear regression coefficients (LRC) as effect estimates. Some studies introduced untransformed PFAS levels in the regression models, while others used log-transformed values. We performed two separate meta-analyses of actual and log-transformed values. We chose 1 ng/ml and the natural logarithm of 1 ng/ml (ln) as the units of measurement for LRC for the untransformed and log-transformed analyses, respectively. We recalibrated LRC and standard error in models using different measurement units and used the base change formula for log-transformed PFAS values to change the base to the natural constant e, as described before in the study of Negri et al. 2017, which had a similar research focus as ours. In addition, we used BW/BW-Z/BW/GA-Z (g), HC/BL (cm), GA (weeks), and PI (g/cm²) as the uniform outcome indicator units. Detailed transformation methods and estimates of the effects extracted before and after standardization are shown in Supplementary Material B (1–10).

In the highest vs. the lowest exposure meta-analysis, if the included studies provided effect estimates for categorical PFAS exposure, we selected high percentile effect estimates vs. low percentile effect estimates (i.e., the fourth percentile vs. the first percentile exposure or the third percentile vs. the first percentile exposure).

The effect estimates used for evidence synthesis were extracted from the “fully adjusted model” or “main model” among the included studies. If studies used the same population cohort and did not differ in composition and follow-up time, we analyzed only the latest date. Fei et al. (60) reported two different sets of birth outcome indicators separately for PTB, LWB, and SGA in the same Danish national birth cohort, while Fei et al. (43) reported indicators for WB, HC, and placental weight; thus, both studies were included. Similarly, Chen et al. (61), following the same Taiwan Birth Panel Study (TPBS), further collected growth indicators in 2017 from participants aged 9 years to the onset of puberty to explore long-term growth effects; thus, both studies were also retained. Four PFAS (PFOA, PFOS, PFNA, PFUA) were included in the study published in 2012 (62), while only two (PFOA and PFOS) were considered in the later study. Maximally adjusted effect estimates (regression coefficients, ORs, and RR) were additionally extracted wherever possible. When the effect estimates for the total population are not available, for example, in studies (39–41) that showed the data for males and females separately, we treated them as separately studies as described by Negri et al. (47) and Dzierlenga et al. (49). We also did the same with Lauritzen et al. (63), which included two cohorts (Norway and Sweden). Moreover, Bjerregaard-Olesen et al. (64) and Hjermitslev et al. (29) reported the sum of perfluorocarbons acid (total PFCA), perfluorosulfonic acid (total PFSA), and total PFAS, and Li et al. (65) measured total PFOA, n-PFOA, total PFOS, n-PFOS, Br-PFOS, 1m-PFOS, iso-PFOS an 3+4+5m-PFOS; we disregarded the division of PFAS subgroups and only analyzed data on total PFAS. All analyses were performed and reported separately for each type of PFAS.

Available data for the main analysis or subgroup analysis were extracted from texts or digitized figures (66–68) from the forest plots reported in studies whose raw data are not available. Specifically, we used Origin 2019b software to digitally transform the image data into extractable data, an approach similar to that of Premaratne et al. (69).

To pool effect estimates across the included studies, we performed a meta-analysis of each exposure-outcome pair with
a random-effects or fixed-effects model based on heterogeneity (71). Most studies reported regression coefficients (β) or ORs, with only one reporting RRs (71); therefore, we removed that study from our meta-analysis. In addition, to compare effect estimates across studies, we normalized all effect estimates in units to 1 ng/ml or 1 ln (ng/ml) difference in PFAS by the following equation formula: \( OR_{\text{standardized}} = e^{(\ln (OR_{\text{origin}}) / \text{Increment}_{\text{origin}} \times \text{Increment}_{\text{standardized}})} \). Meanwhile, we assessed heterogeneity using the I^2 statistic (greater than 50% is considered to indicate substantial heterogeneity) (Higgins et al. 2003) and the \( p \)-value of the chi-squared test for heterogeneity (less than 0.1 indicates statistical significance) (72). Additionally, univariate meta-regression for gender, timing category of blood sample collection, study design, geographic region, blood collection matrix, outcome assessment and adjustment of GA, and parity for birth outcome were conducted to identify sources of heterogeneity that included more than 10 studies (73). Moreover, we assessed publication bias using Egger’s test (72). We further assessed publication bias using Doi plots and the Luis Furuya-Kanamori (LFK) index (< 1, “no asymmetry”; between 1 and 2, “slight asymmetry”; > 2, “severe asymmetry”), taking into account the inaccuracy of statistical and graphical methods in assessing publication bias in a few studies (74). Additionally, a sensitivity analysis was conducted to assess stability of the results, specifically by recalculating the pooled effect estimates by excluding individual studies in turn.

All analyses were conducted with Stata version 14 (StataCorp LP, College Station, TX, USA) and MetaXL v.5.3 software (EpiGear International Pty Ltd, Sunrise Beach, Queensland, Australia, www.epigear.com). Studies that failed to qualify for the meta-analysis but investigated relevant pairs of associations were analyzed by descriptive summary. Additional subgroup analyses were conducted to further assess whether the pooled effect estimates remained robust across gender, timing category of blood sample collection, study design, geographic region, blood collection matrix, outcome assessment, and adjustment of GA and parity.

**Confidence Ratings of the Body of Evidence and Translation of Evidence Levels**

According to the NTP/OHAT framework, we assessed the body of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guideline (75). The NTP/OHAT framework was used to assess the quality and strength of the evidence because it was consistent with the causality criteria of Hill. In brief, observational studies exhibit low to moderate initial confidence ratings for the lack of control in assigning exposures. The initial confidence of the evidence body was determined by the key study design features. Then, we evaluated each exposure-outcome pair, with either five factors lowering initial confidence or four factors increasing initial confidence. The final confidence of each exposure-outcome pair was divided into four descriptors: “high,” “moderate,” “low,” or “very low.” Reliability is translated into “high,” “moderate,” “low,” “inadequate,” or “evidence of no effect on health” levels of epidemiological evidence, depending on the confidence of different exposure-outcome pairs.

**RESULTS**

**Study Selection and Characteristics**

After excluding duplicates, we retained a total of 918 papers for title/abstract screening. As shown in Figure 1, we conducted a full-text search of 58 relevant articles, of which 46 provided available data on PFAS and birth outcomes that could be pooled for meta-analysis as well as evaluation (12–14, 20, 29, 36–39, 41, 43–46, 57, 60–68, 71, 76–95). Among them, 2 publications (96, 97) examined the association between PFAS and reproductive distance, while 3 articles (98–100) focused on the association between PFAS exposure in the environment and birth outcomes. These five studies were separately synthesized again in a descriptive manner.

The characteristics of the included studies are summarized in Supplementary Table 3. Years of publication ranged from 2007 to 2021, with 13 new articles after Steenland et al. (48) published the previous meta-analysis (PFOA and BW). Two different studies from Norway and Sweden were described in one article (63), and studies (39–41) only presented separate data for gender subgroups and did not aggregate and summarize data for the population at large, resulting in the smaller volume of included documents than the studies. Of the included studies, 16 were from Asia, 15 were from Europe, 10 were from North America, and 3 were from Oceania. In particular, the population of Lenters et al. (45) consisted of people from Greenland, Poland, and Ukraine. In addition, 37 studies were longitudinal, including 33 cohort studies and 4 case-control studies, while the remaining 9 were cross-sectional studies. The included study subjects ranged from 85 to 11,737. The vast majority of study subjects had outcome measures at birth (i.e., early fetal life), but Chen et al. (61) and Cao et al. (36) extended those measures to 24 weeks postpartum to better explore the long-term effects of PFAS exposure. Notably, 16 studies focused on sex differences, while Marks et al. (37) included only male infants and Maisonet et al. (44) included only female infants. Eight studies investigated differences in the timing of blood sample collection. Twenty-nine studies had blood samples from serum, 14 studies had blood samples from plasma, and the remaining 4 studies had blood samples from whole blood collected at 0 (preconception) to 40 weeks (cord blood at term). For exposure assessment, 43 studies of PFOA and 40 studies of PFOS were included. Furthermore, for continuous data, 41 studies examined BW indicator, 21 studies examined BL, 16 studies examined HC, and 13 studies examined each of GA and PI; for categorical data, 11 studies examined PTB, 6 studies examined LBW, and 7 studies examined SGA. Forty studies assessed the corresponding birth indicators by clinical examination, and 3 studies were self-reported by questionnaires. Of interest, 28 studies adjusted for GA as an independent confounder, and 30 studies adjusted for parity.
Study Quality and Risk-of-Bias Assessment

The studies included in our meta-analysis could be considered moderate to high quality, with scores between 0.77 and 0.94 based on quality assessment (Supplementary Table 3). Supplementary Table 11 shows the results of the RoB assessment of the meta-analysis studies using heat maps. We had predetermined criteria for the assessment of quality exposure from body fluids, with 7 studies classified as “definitely low” and all the remaining included studies (n = 39) rated as “definitely low” for RoB. Regarding the RoB of outcome assessment, 11 studies were classified as “definitely low,” 1 study as “probably high” (101) and 1 as “definitely high” (82) because of their deficiencies in medical record validation. For confounding bias in the included studies, 6 were rated as “definitely low” RoB, 14 as “probably low” RoB, 20 as “probably high” RoB, and 6 “definitely high” RoB because they ignored the main confounding factor GA and parity and adjusted for too few confounders. Moreover, given the inherent characteristics of cross-sectional vs. longitudinal studies and the way control groups were matched,
FIGURE 2 | Meta-analysis of the associations of PFOS and PFOA with birth weight (g) for per 1 ln(ng/ml) increment of exposure.
FIGURE 3 | Meta-analysis of the associations of PFNS, PFUnDA and PFDA with birth weight (g) for per 1 ln(ng/ml) increment of exposure.
### FIGURE 4 | Meta-analysis of the association of PFOS, PFOA, PFHxS and PFHpS with birth weight (g) for top versus bottom categories of exposure.

| group and Study                      | Regression Coefficients (95% CI) | % Weight |
|--------------------------------------|----------------------------------|----------|
| **PFOS for top versus bottom**       |                                  |          |
| Apelberg et al. 2007                 | -58.00 (-125.00, 9.00)           | 11.22    |
| Fei et al. 2008                      | -10.80 (-33.40, 111.80)          | 9.56     |
| Maisonet et al. 2012                 | -140.01 (-238.14, -41.89)        | 5.23     |
| Darrow et al. 2013                   | -54.00 (-128.00, 17.00)          | 9.58     |
| Bach et al. 2016                     | -58.00 (-105.00, 8.00)           | 15.78    |
| Starling et al. 2017                 | -71.10 (-142.60, 0.50)           | 9.84     |
| Cao et al. 2018                      | -17.60 (-141.20, 106.00)         | 3.30     |
| Meng et al. 2018                     | -48.20 (-99.00, 2.50)            | 19.56    |
| Marks et al. 2019                    | -83.88 (201.43, 33.68)           | 3.64     |
| Wikstrom et al. 2020                 | -80.00 (-144.00, -16.00)         | 12.30    |
| Subgroup, DL (I² = 0.0%, p = 0.776)  | -59.09 (-81.53, -36.64)          | 100.00   |
| **PFOA for top versus bottom**       |                                  |          |
| Apelberg et al. 2007                 | -58.00 (-119.00, 3.00)           | 12.08    |
| Fei et al. 2008                      | -21.30 (-46.10, 3.40)            | 19.05    |
| Maisonet et al. 2012                 | -133.45 (-237.37, -29.54)        | 6.59     |
| Darrow et al. 2013                   | 0.00 (-68.00, 69.00)             | 10.84    |
| Bach et al. 2016                     | 9.00 (-47.00, 64.00)             | 13.07    |
| Starling et al. 2017                 | -92.40 (-166.20, -18.50)         | 10.03    |
| Cao et al. 2018                      | -26.30 (-149.10, 96.40)          | 5.17     |
| Meng et al. 2018                     | -117.00 (-172.30, -61.60)        | 13.09    |
| Marks et al. 2019                    | -45.96 (-170.83, 78.92)          | 5.04     |
| Wikstrom et al. 2020                 | -90.00 (-159.00, 91.00)          | 5.03     |
| Subgroup, DL (I² = 54.9%, p = 0.018) | -51.48 (-83.52, -19.44)          | 100.00   |
| **PFHxS for top versus bottom**      |                                  |          |
| Maisonet et al. 2012                 | -107.93 (-206.18, -9.69)         | 8.89     |
| Bach et al. 2016                     | -49.00 (-109.00, 11.00)          | 23.84    |
| Starling et al. 2017                 | -31.80 (-105.80, 42.20)          | 15.67    |
| Cao et al. 2018                      | -25.10 (-149.10, 98.90)          | 5.58     |
| Meng et al. 2018                     | 8.60 (-59.70, 76.90)             | 18.40    |
| Marks et al. 2019                    | -53.87 (-173.65, 65.91)          | 5.98     |
| Wikstrom et al. 2020                 | -6.00 (-69.00, 57.00)            | 21.63    |
| Subgroup, DL (I² = 0.0%, p = 0.577)  | -30.60 (-59.90, -1.31)           | 100.00   |
| **PFHpS for top versus bottom**      |                                  |          |
| Bach et al. 2016                     | -43.00 (-100.00, 14.00)          | 54.25    |
| Meng et al. 2018                     | -102.60 (-169.00, -36.20)        | 45.75    |
| Subgroup, DL (I² = 43.9%, p = 0.182) | -70.27 (-128.46, -12.07)         | 100.00   |

Heterogeneity between groups: p = 0.427
17 studies were rated as “definitely low” or “probably low” for selectivity bias, while 4 studies were rated as “probably high” and 8 studies were rated as “definitely high,” respectively. Nevertheless, for attrition/exclusion bias, four studies were rated as “definitely low” for the RoB. However, the study of Maisonet et al. (44) was rated as “probably high” because the authors stated to observe changes in the magnitude and direction of the bivariate associations arising after excluding some of the data, and other studies without explicit exclusion bias were rated as “probably low.” Additionally, for selective reporting bias, one study (81) was rated as “definitely low” for RoB because the results included in the meta-analysis provided sufficient detail for reporting, 3 studies were rated as “probably low” because of indirect reporting of results, and the rest studies were rated as “probably low” RoB. The authors of most studies declared no conflicts of interest, and four studies that did not report conflicts of interest or financial support were rated as “probably high.”

In summary, all eligible studies were categorized as either tier 2 \( (n = 17) \) or tier 1 \( (n = 29) \) of the RoB, indicating that there may be some reasonable bias that casts some doubt on the results.

**Data Synthesis**

**Meta-Estimates for Associations of PFAS With BW (g)**

The summary regression coefficient for the association of per 1 ln (ng/ml) increase in exposure to any type of PFAS was \(-0.110\) (95% CI: \(-0.246, 0.026\), \(p\)-value < 0.001), and for per 1 ng/ml was \(-0.016\) (95% CI: \(-0.029, -0.002\), \(p\)-value = 0.159), while the highest vs. the lowest level was \(-0.106\) (95% CI: \(-0.221, 0.008\), \(p\)-value < 0.001) using random-effects models (Supplementary Table 12). The overall \(I^2\) was 18.3% to 56.7%, indicating low to moderate between-study heterogeneity.

The type of PFAS demonstrated different effects on BW and vice versa (Figures 2–4). We found that PFOS \((-0.002\) per 1 ng/ml increase), PFHpS \((-181.209\) per 1 ng/ml increase and \(-70.267\) for the highest vs. the lowest level exposure), and PFDA \((-24.252\) per 1 ln (ng/ml) increase) reduced BW (all types), like most PFAS, although others still had some regression coefficients with 95% CIs covering 0. In turn, the type of BW also showed a differential sensitivity to PFAS, for unstandardized BW, there exhibited statistically significant reductions in the case of the following PFAS: PFOS \([-34.882\) per 1 ln (ng/ml) increase and \(-59.085\) for the highest vs. the lowest level exposure], PFOA \([-37.017\) per 1 ln (ng/ml)
increase and $-51.482$ for the highest vs. the lowest level exposure], PFHxS $(-30.604$ for the highest vs. the lowest level exposure), PFNA $[-28.312$ per 1 ln (ng/ml) increase], PFUnDA $[-16.485$ per 1 ln (ng/ml) increase], PFHpS $(-181.209$ per 1 ng/ml increase and $-70.267$ for the highest vs. the lowest level exposure) and PFDA $[-24.252$ per 1 ln (ng/ml) increase]. In contrast, for standardized (GA adjusted) BW, only PFOS $[-0.002$ per 1 ln (ng/ml) increase and $-0.133$ per 1 ln (ng/ml) increase] and PFNA $(-0.1$ per 1 ng/ml increase, $n = 1$) showed statistically significant reductions. Overall, the heterogeneity of studies related to BW and PFAS was low, even after we classified BW by “standardized” vs. “non-standardized” and by continuous or categorical data (Supplementary Table 12).

Overall, exposure to PFOS, PFHpS, PFDA decreased BW, and exposure to PFOS, PFOA, PFHxS, PFNA, PFUnDA, PFHxS, PFDA decreased BW (without GA adjustment), and exposure to PFOS, PFNA decreased BW-Z score, while the other PFAS did not show statistically significant effects (Supplementary Table 12).

Meta-Estimates for Associations of PFAS With BL (cm), HC (cm), and PI (g/cm$^3$)

The meta-analyses indicated that exposure to PFOS ($n = 3$, $-0.034$, 95% CI: $-0.062$ to $-0.005$, per 1 ng/ml increase) and PFOA ($n = 4$, $-0.301$, 95% CI: $-0.529$ to $-0.073$, the highest vs. the lowest level exposure) showed statistically significant decrease in BL (Figure 5), and the corresponding meta-analyses were of low heterogeneity ($I^2 = 0.0$% and 36.6%), with regression coefficients varied from $-0.301$ (PFOA, $n = 3$) to 0.420 (PFHpA, $n = 1$), which was similar to the case of continuous or categorical exposure (Supplementary Table 12).

The meta-analyses indicated that exposure to PFOS ($n = 2$, $-0.021$, 95% CI: $-0.038$ to $-0.004$ per 1 ng/ml increase) and PFDoDA ($n = 4$, $-0.085$, 95% CI: $-0.164$ to $-0.006$ per 1 ln (ng/ml) increase) showed statistically significant decrease in HC and with non-significant heterogeneity ($I^2 = 0.0$% and 0.0%), which were similar to the results of BL (Figure 6). The regression coefficients varied from $-36.900$ (PFHpA, $n = 1$) to 0.066 (PFOA, $n = 2$) (Supplementary Table 12).
The meta-analyses indicated that only exposure to PFOS ($n = 2$, $-0.355$, 95% CI = $-0.702$ to $-0.008$ per 1 ng/ml increase) and PFOA ($n = 3$, $-0.412$, 95% CI = $-0.787$ to $-0.037$ per 1 ng/ml increase) showed statistically significant decrease in PI and no heterogeneity ($I^2 = 0.0\%$ and 0.0%), with regression coefficients varied from $-0.412$ (PFOA, $n = 2$) to 0.100 (PFNA, $n = 1$ and PFDA, $n = 1$) (Supplementary Table 12).

Overall, exposure to PFOS, PFOA, PFDoDA decreased BL, exposure to PFOS, PFDoDA decreased HC, exposure to PFOS, PFOA decreased PI, while the other PFAS did not show statistically significant effects (Supplementary Table 12).

### Meta-Estimates for Associations of PFAS With GA (Weeks)

The meta-analyses indicated that only PFHpS ($-0.232$, 95% CI = $-0.367$ to $-0.097$, per 1 ln (ng/ml) increase and $-2.000$, 95% CI = $-3.300$ to $-0.700$, for the highest vs. the lowest level exposure) showed statistically significant decrease in GA, and there was no heterogeneity ($I^2 = 0.0\%$) (Figure 7), with regression coefficients ranging from $-2.000$ (PFHpS, $n=1$, for the highest vs. the lowest level exposure) to 0.180 (PFOSA, $n=1$, for the highest vs. the lowest level exposure). Overall, exposure to PFHpS reduced GA, while the other PFAS did not show statistically significant effects (Supplementary Table 12).

### Meta-Estimates for Associations of PFAS With PTB, LBW, and SGA

For PTB, exposure to PFOA (13.3% for categorical exposure), PFOS [23.7% per 1 ln (ng/ml) increase, 0.6% per 1 ng/ml increase and 39.4% for categorical exposure], PFHxS [1.7% per 1 ln (ng/ml) increase and 17.8% for categorical exposure], PFNA (57.7% per 1 ng/ml increase and 75.3% for categorical exposure), PFHpS [73.5% per 1 ln (ng/ml) increase and 80% for categorical analysis] and PFOSA (60% for categorical exposure) were associated with non-significant increased risk (Supplementary Table 12).

For LBW, exposure to PFOS [21.3% per 1 ln (ng/ml) increase and 35.2% for categorical exposure], PFOA [2.3% for categorical exposure], PFHxS [3.4% per 1 ln (ng/ml) increase] or PFNA [50.0% for categorical exposure], PFUnDa [1.0% per 1 ln (ng/ml) increase] and PFDA [28.1% per 1 ln (ng/ml) increase] were also associated with non-significant increased risk (Supplementary Table 12).

For SGA, exposure to PFOS [21.4% per 1 ln (ng/ml) increase], PFOA [21.6% per 1 ln (ng/ml) increase and 16.8% for
categorical exposure], PFHxS (4% for categorical exposure) or PFNA (7.4% per 1 ln (ng/ml) increase and 23% for categorical exposure], PFUnDa [10.4% per 1 ln (ng/ml) increase and 52% for categorical exposure] and PFDA [46% per 1 ln (ng/ml) increase and 50% for categorical exposure], PFDoDa [13.8% for per 1 ln (ng/ml) increase], PFHpA [6% per 1 ln (ng/ml) increase and 25% for categorical exposure] and PFDeA [42% for per 1 ln (ng/ml) increase] were associated with increased risk; however, most of them are non-significant (Supplementary Table 12).

Overall, exposure to PFNA, PFHpS increased the risk of PTB, exposure to PFDA increased the risk of SGA, while the other PFAS did not show statistically significant effects (Supplementary Table 12).

**Subgroup Analysis**

Supplementary Table 13 shows the results of subgroup analyses by fetal gender, time of blood sample collection, blood sample type and whether adjusted for GA/parity, study design, and geographic region.

Subgroup analyses for gender suggested that the associations of PFAS with birth outcome may modify by gender; for example, girls in PFOS/PFOA–BW showed a stronger variation in the effect estimates than boys for the highest vs. the lowest level exposure. However, continuous exposure did not show significant differences by gender (Supplementary Tables 10, 13). Meanwhile, regarding time of blood sample collection, similar details were shown in Supplementary Tables 10, 13. Furthermore, when subgroup analyses were performed by study design (Supplementary Tables 10, 13), effect estimates were influenced by it for some of the exposure-outcome pairs. Additionally, in the combination of PFOS with BW, effect estimates were different for studies performed in Asia (n = 12, −44.792, −76.694 to −12.889), Europe (n = 7, −49.645, −88.805 to −10.486) and North America (n = 5, −0.002, −0.004 to 0). Results for the subgroup analyses by blood sample type and whether adjusted for GA/parity also indicated that these factors may modify the associations of some exposure and outcome combinations.

**Small-Scale Studies on Environmental Exposure to PFAS**

In addition to our meta-analysis, 3 similar papers also examined the effects of PFAS on birth outcomes among populations with known exposure to high level PFAS in contaminated environments. Nolan et al. (98) investigated the associations in Little Hocking Water Association (LHWA) cohort in Washington County, Ohio, where serum PFOA levels were ~80 times higher than those in the general US population. This cross-sectional study included 1,555 singleton newborns and suggested that exposure to high level of PFOA was associated with neonatal birth weight, PTB and gestational age. Similarly, Manea et al. (100) published a study in 2019 that was performed from 2003 to 2018 including 105,114 singleton live births, which focused on the risk of severe SGA in PFAS-contaminated areas. The results showed that exposure to PFAS-contaminated areas is significantly associated with an increased risk of SGA.

The Effects of PFAS on the Anogenital Distance (AGD) of New-Born

Our systematic review found two additional cohort studies from Canada and Denmark examining the relationship between prenatal exposure to PFAS and AGD. Lind et al. (96) examined the association between levels of PFOS, PFOA, PFHxS, PFNA, and PFDA and AGD in the Odense Children's Cohort, which showed a sexually dimorphic effect of PFOS on AGD. Arbuckle et al. (97) assessed the association between AGD in 401 newborns and PFOA, PFOS and PFHxS in maternal plasma in early pregnancy in the MIREC cohort, which showed that for a 1 ln (ng/ml) increase in PFOA exposure, AGD increased by 1.36 mm (95% CI: 0.30, 2.41), but the statistical significance disappeared in either categorical exposure analysis or gender subgroups.

Other Types of Birth Outcome Indicators

We identified additional 11 studies assessing the associations of miscarriage and 1 study assessing stillbirth with PFAS exposure. Savitz et al. (101) did not find a significant association between estimated PFOA exposure and stillbirth after they examined multiple birth outcome indicators in pregnant women in areas with high exposure to PFOA-contaminated water (located in West Virginia and Ohio). In terms of miscarriage, Two studies (81, 102) performed by Darrow et al. were considered as duplicates, and only Darrow et al. (102) was included because both studies were based on the same cohort and no updates were available. Similar studies (36, 80, 94) involved only descriptive analysis and failed to provide extractable data. Louis et al. (103) examining the relationship between PFAS and pregnancy loss, they did not give an explicit indicator of miscarriage (their definition of “pregnancy loss” was significantly different from miscarriage). Stein et al. (104) found that exposure to neither PFOA nor PFOS showed an association with miscarriage for the populations live in the Central Ohio Valley region. We standardized the data of Darrow et al. (102) and Jensen et al. (105), which produced the ln-transformed data and for Liew et al. (106), doubling data were provided, and the specific transformation method was described above. We performed a meta-analysis on the remaining 3 studies and found that with exception of PFDA (OR = 2.293, 95% CI: 1.252, 4.201, for the highest vs. the lowest level exposure), others (PFOA, PFOS, PFHxS, PFNA, PFHpS, PFOSA) were statistically significantly associated with miscarriage. However, considering that half of the tested exposure-outcome pairs included fewer than 3 studies, further expansion of the sample size is needed to determine the association between PFAS and miscarriage.

**Sensitivity Analysis and Publication Bias**

The results of sensitivity analyses are presented in Supplementary Tables 6–8. Most of the results did not substantially change, which indicated the stability of our results. Meta-regression analyses for the exposure-outcome pairs containing at least 10 observations per covariate (i.e., gender for PFOS/PFOA/PFHxS/PFNA-BW, time of sample collection for PFOS/PFOA/PFHxS/PFNA/PFDA-BW, and other covariates for PFOS/PFOA-BW/HC/BL and PFOA-GA) indicated that
heterogeneity may derive from adjustment of parity for PFOA-GA (\(p = 0.039\)), study design for PFOA-HC/BW (\(p = 0.020\) and \(p = 0.040\)), adjustment of GA for PFOA/PFNA-BW (\(p = 0.047\) and \(p = 0.031\)). It was also noteworthy that when meta-analyses were conducted under the quality effect models (Supplementary Figures 1–65), significant differences were found only in the combinations of PFOA/PFOA/PFDA-BW, PFDoDA-BL and PFHpS-GA for per 1 ln (ng/ml) increment in exposure, PFOA-PI and PFOS-BL for per 1 ln (ng/ml) increment in exposure, PFOA-BL/HC, PFOS-BW and PFNA-PTB for the highest vs. the lowest categories of exposure. Moreover, we detected publication bias in some of the exposure-outcome pairs, as shown in Supplementary Table 12. However, among the 75 exposure-outcome pairs (\(n \geq 3\)), Doi plots and the LFK index suggested publication bias (major asymmetry) in 61 of the 75 pairs (Supplementary Figures 34–65).

Confidence Rating and Level of Evidence Translation

Supplementary Table 9 shows the results of our summary on confidence ratings for each exposure-outcome pair in the body of evidence. The NTP/OHAT framework stipulates that only controlled and experimental studies should initially be rated as “high confidence,” so all included observational studies were rated as “moderate confidence” throughout our rating process. Most of the studied pairs with significant associations were assessed as moderate confidence, and thus were translated to “moderate level” of epidemiological evidence.

DISCUSSION

To the best of our knowledge, the present study is the largest and most comprehensive systematic review and meta-analysis combining all PFAS exposure types available with all birth outcomes available. It has been well documented that newborns can be prenatally exposed to a wide variety of PFAS through placental transfer. Therefore, over the past decades, an emerging body of cross-sectional studies did not show temporal associations; thus, the possibility of reverse causality cannot be ruled out. Wang et al. (40) found a reduction in birth size and GA for girls and boys when exposed to PFNA and PFDoDA, while several studies (66, 67, 85) found that a reduction in BW with PFOA exposure was presented only in male rather than female fetuses. Interestingly, Manzano-Salgado et al. (66) and Fei et al. (43) found a reverse association on the combination of PFOS with BW, which suggesting that there is indeed a modify effect of gender in associations between different types of PFAS and birth outcomes. With regards to the timing of blood sampling, its effect on birth outcomes has been widely noted for a long time. Meanwhile, the differences in PFAS concentrations between different stages of labor and in cord blood (at term) have been greatly studied. For example, Dzierlenga et al. (49) illustrated that PFOA levels vary by gestational length and decrease during pregnancy, possibly due to pregnancy-related blood volume expansion or parallel increase in glomerular filtration rate. Other studies (48, 79) have further indicated that there is an undetermined reverse causality in the blood during pregnancy, which can affect the feasibility of the conclusions.

Different birth outcome indicators may represent different pathogenic mechanisms. BW and BL have traditionally been proposed as the two main indicators that could reflect short-term and long-term fetal growth and development (especially nutritional status), respectively, representing the fetal development in utero. The BW-Z score, BW/GA-Z score or WAZ (age-specific Z-scores for weight) is a measure of BW that standardized to total body mass using US reference data for GA, adjusted for the effect of GA on fetal growth and development to some extent. Similar indicators are weight-for-age, length-for-age, weight-for-length, and body mass index (BMI) Z-scores. The PI is measured by birth weight (g)/(birth length (cm)) \(^2\) * 100 and is used as a proxy for body weight that takes into account the effect of body length on body mass. It was first introduced in the early 1920s and is widely used to assess the growth and development of newborns and young children, similar to the BMI...
of adults (35, 93). In particular, BW values are easier to obtain than PI or BW-Z score values because only one measurement is required. This may partly explain the inconsistencies in our subgroup analysis of BW (crude weight, weight-Z index, PI) and the contradictory results of previous study (91). HC is closely related to brain and cranial growth as well as biparental growth and can reflect brain development or other brain disorders (e.g., hydrocephalus) and neurological completeness (37, 64). The timing effects of different PFAS on fetal development was significant because several indicators were closely related to time periods: the increasing of number and volume of fetal brain cells and the formation of cortical gyri are developed during the first trimester of pregnancy while the proliferation of brain cells occurs at 20 weeks of gestation and the active growth of brain cells lasts from 30 weeks of gestation to delivery. It is also worth noted that GA, as an intermediate variable for other birth outcome indicators (e.g., BW), is associated with BW and cumulative PFAS exposure. Some studies indicated that adjusting for GA would result in a positive association of PFOA with BW. However, adjustment of GA does not affect the relationship between PFOA and BW, which is also supported by the present study, although more than half of the included studies suggest that GA is unlikely to be a confounding or intermediate variable (62, 77). In any case, GA should be given adequate attention and treated appropriately as an important variable in future studies. In addition, age and gender differences in the measurement of birth and developmental indicators are also of great concern (40, 41).

Our results revealed that different types of PFAS result in differences in the sensitivity of different outcome indicators for PFAS with different molecular weights and backbone lengths. Specifically, BW was observed to appear to be significantly reduced when exposed to PFOS (per 1 ng/ml: −34.882), PFNA (per 1 ng/ml: −28.312), PFUnDA (per 1 ng/ml: −16.485), PFDA (per 1 ng/ml: −24.252), PFOA (highest vs. lowest: −51.482), PFHxS (highest vs. lowest: −30.604), PFHpS (highest vs. lowest: −70.267). By comparison, BL had the opposite significant effects when exposed to PFOS (per 1 ln (ng/ml): +0.034), PFOA (per 1 ln (ng/ml): −0.148), and PFUnDA (highest vs. lowest: 0.410). Meanwhile, PTB showed statistically significant differences in exposure to PFNA (57.7%) and PFHpS (73.5%). Similar results for other birth outcome indicators corresponding to one or more specific types of PFAS are described in Supplementary Table 13. These findings have been widely reported in previous studies (38, 100). Callan et al. (83) even found that PFHxS and PFUnDA seem to have completely opposite effects on the increase of optimal BW ratio.

Our subgroup analyses demonstrated the modify effect of gender in the associations of birth outcome indicators with prenatal PFAS exposure, such as, in PFOS and BW combination [male: −45.073 (−104.248, 14.102) and female: −111.402 (−180.314, −42.490)] (Supplementary Table 13), which was also found by previous studies (13, 40, 41, 68). One of these studies (40) found that prenatal exposure to PFDoDA was associated with reduced HC in girls but not in boys. Wikstrom et al. (13) and Chen et al. (12) shared a similar finding that PFOS had a greater negative effect on weight in girls than in boys, and similar findings were also observed in other studies (40, 77, 107). Furthermore, the modify effect of gender seems to be more pronounced in an inverse relationship between long-chain PFAS exposure and height (61) as well as weight later in life (40). The potential mechanism involved may be related to the effect of PFAS on human sex hormone biosynthesis (34, 39), insulin-like growth factor-1 serum levels (35) and estrogen receptor function (33), even though some in vitro tests remain questionable (108).

It should be noted that maternal blood samples were collected at different times during gestation, which was presumed to have significant differential effects in our subgroup analysis (Supplementary Tables 10, 13). Chen et al. (12) found that indicators of birth somatic measurements mainly appeared in the first trimester by analyzing single and multiple time points, further suggesting that primary ossification centers, affected hormones and high PFAS levels resulted in a “sensitive window” in the first trimester that affects fetal skeletal growth. In contrast, some studies (13, 47, 48) suggest that differences in the timing of blood sampling on birth outcome indicators may arise from two sources: first, PFAS level during pregnancy are affected by the diluting effect of the expanded blood volume during pregnancy, as well as by the accompanying decrease in serum albumin levels; second, PFAS level during pregnancy decreases due to the diluting effect of the expanded blood volume during pregnancy, and result in decreasing serum albumin levels and placental and fetal uptake. Salas et al. (109) found that in the third trimester to delivery, the median level of maternal serum PFOA decreased from 2.4 to 1.9 ng/ml. Fromme et al. (110) and Chen et al. (12) found that most PFAS levels, with exception of elevated PFBS level, decreased as pregnancy progressed, while PFHxS level remained unchanged (109, 111), which seems to be inherently related to the properties of PFAS (e.g., transrenal excretion of short-chain PFAS). The association between maternal blood volume and fetal growth has been demonstrated by Fromme et al. (110). Additionally, the differences in transplacental transfer of different PFAS lead to differences in PFAS level in maternal vs. cord blood. Kato et al. (112) found maternal and cord serum concentrations of PFOA to be ∼1:1 and PFOS to be ∼2:1. Therefore, the combined effect of changes in renal function and plasma volume may affect fetal growth and development in multiple ways by modulating PFAS levels through actions including reverse causality (12, 51). In fact, the glomerular filtration rate (GFR) can affect both PFAS level and birth outcomes, with Steenland et al. (48) found that late gestational blood corresponds to a greater GFR (40–50% increase), mainly in the third trimester. As Verner et al. (113) reported, babies with smaller BW tend to have mothers with lower GFRs, and indeed, higher levels of PFAS in blood do correspond to lower GFRs. The pharmacokinetics of PFAS during pregnancy may modulate fetal growth through reverse causality, as discussed in detail by Johnson et al. (51). Additionally, GFR may play a confounding or reverse causality role by affecting the renal clearance of different types of PFAS; for example, as for identical short-chain PFAS, renal function changes during pregnancy have a greater impact on PFBS (half-life 25.8 days) than on PFHxS (half-life 8.5 years). However, more evidence is needed to further clarify the role of changes in PFAS levels during
pregnancy, PFAS structure, GFR and serum albumin in distorting the results.

In addition, the choice of data log-transformed or untransformed in the analysis should be carefully considered, given that dose-response relationships such as the “plateau phenomenon” (114) associated with exceeding background doses are not well studied for different PFAS. Darrow et al. (81) and Savitz et al. (78) found that log-transformed for PFOA is better in fitting data than untransformed. However, Steenland et al. (48) calculated the QIC [the goodness of fit statistic, analogous to the AIC (Akaike information criterion)] and concluded that the linear model was similar to the log-transformed model in terms of QIC, indicating that the two models in fitting the data are approximately well for PFOA at serum levels below 10 ng/ml. Furthermore, given the ambiguity of the dose-response relationship in the multiple PFAS-birth outcome pairs, we referred to the study of Negri et al. (47) for direct separate analyses without model reprocessing, and we did detect differences in the linear vs. log-transformed fit models (Supplementary Tables 6–10, 13, 14). However, this still requires a larger number of studies for in-depth interpretation.

Several mechanisms by which PFAS interferes with fetal development and growth have been proposed to explain some of the putative effects. Vanden Heuvel et al. (115) suggest that PFAS may be involved in the processes of insulin signaling, and regulation of glucose and lipid metabolism by activating peroxisome proliferator-activated receptor-alpha (PPARα) or PPARγ. Callan et al. (83) also observed alterations in lipid metabolism and thyroid hormone levels. The correlation of serum leptin and adiponectin levels, triglyceride concentrations, and insulin and HOMA-IR (homeostasis model assessment of insulin resistance) indices with PFAS has also been confirmed by in vivo in vitro trials (116, 117). In addition, Goudarzi et al. (118) found a negative association between PFOS and cord blood glucocorticoids, and an inverse relationship between PFAS and unsaturated fatty acids. PFAS is structurally similar to fatty acids; thus, Callan et al. (83) suggested that PFAS are likely to affect fatty acid metabolism. It is worth noted that some researchers proposed that different types of PFAS may involve different mechanisms. Fletcher et al. (119) reported an inverse and positive association between serum PFOA and PFOS levels and transcripts involved in cholesterol metabolism, respectively, in the C8 group. Unfortunately, the available evidence for this proposal is scarce. The existing experimental exposure doses in rodents are often 100–1,000 times higher than the human exposure level (47); thus, there is an urgent need to further clarify the different properties of the various PFAS and derivatives.

As previously described, the five available meta-analyses were flawed in either research methods or research design. Negri et al. (47) (PFOS and PFOA) examined BW with the number of included studies ranging from 12 to 29 and did not include additional literatures beyond 2020 (n = 8). Johnson et al. (51) aimed to examine associations of PFOA with multiple birth outcomes (BW, BL, PI, WC) but was quite inadequate in the number of included studies. Some studies (48, 49, 51) transformed data in log-transformed form, while Negri et al. (47) performed separate meta-analyses of log-transformed and untransformed data as two groups. The highlight is that Deji et al. (50) recently published a meta-analysis that attempted to analyze the association between PFOA, PFOS, PFNA, PFHxS and PTB, miscarriage, and stillbirth, but they incorrectly included two inappropriate studies. The first is Louis et al. (103), who examined the association between PFAS and “pregnancy loss,” which is fundamentally different from “miscarriages” or “stillbirth,” as we have described above. The other is Bjerregaard-Olesen et al. (120), who provided back-exponentiation of the linear parameter estimates [relative levels (RL)] of the association between PFAS and the number of miscarriages in 1,438 Danish pregnant women from 2008 to 2013. However, Deji et al. (50) directly combined RL values with other effect estimates (e.g., OR), without any interpretation, which is inappropriate. Additionally, they incorrectly combined log-transformed and untransformed data directly, and these effect estimates extracted from the continuous exposure analysis and the estimates used to generate the meta-analysis were inconsistently scaled and standardized so that the conclusions drawn had to be reconsidered. In addition, all of these studies have inappropriately combined effect estimates from categorical and continuous exposure analyses for the same exposure and outcome pair, confounding the hypothesis of a dose-response relationship as previously described. Only Johnson et al. (51) used the Navigation Guide systematic review methodology to determine the quality of the included studies in terms of risk of bias and level of evidence. Finally, a review from the United States examined the relationships of exposure to toxic metals and PFAS with preeclampsia and preterm delivery, but they did not directly attempt to synthesize the association between PFAS and preterm delivery. Dzierenga et al. (49) and Steenland et al. (48) considered the effect of the time of blood sampling on outcomes, but they did not perform subgroup analyses of gender or other population characteristics.

The present study outweighs the existing meta-analyses in the following aspects. The greatest advantage is that our updates included the most recent studies, and only our study combined the various types of PFAS and birth outcome indicators available. In addition, we analyzed the effects of gender and time of blood collection by subgroup analyses. Furthermore, only our study adopted the NTP/OHAT framework, which is a recommended standard for conducting systematic reviews in the field of environmental health. Moreover, this study also performed meta-regression analysis to explore the source(s) of heterogeneity.

Equally strikingly, the results of the meta-analyses under the random-effects model and the quality-effects model were inconsistent. That is, only PFOA/PFOS/PFDA–BW, PFDoDA–BL and PFHpS–GA per 1 ln (ng/ml) increase in exposure; PFOA–PI and PFOS–BL per 1 ln (ng/ml) increase in exposure; and PFOA–BL/HC, PFOS–BW and PFNA–PTB for the highest vs. the lowest categories of exposure showed significant differences. The conflicting results suggest the need for further research to determine the relationship between each exposure and outcome.

STRENGTHS AND LIMITATIONS

This study provides the most recent and comprehensive synthesis of evidence on the association of PFAS with birth outcomes. Birth outcome indicators including WC, BL, and GA were examined for the first time, and significant associations were discovered
between several PFAS-birth outcome pairs, with almost all of the significant findings showing little heterogeneity. The key strengths of this study are the inclusion and broad coverage of the most recent research evidence, the rigorous, transparent, and reproducible assessment of the evidence, the use of standardized data processing methods to preserve the originality of the data as much as possible, and the comprehensive and systematic elucidation of the potential role of different types of PFAS exposure in increasing the risk of adverse birth outcomes. This study makes a prompt contribution to the rapidly evolving field of research, illuminates the changes confronting meta-analysis, and provides recommendations for improving the potential utility of future studies.

Despite these advantages, several limitations should be acknowledged. First, the associations of many other exposure-outcome pairs were not explored by our meta-analysis. This is because some other types of PFAS were inadequately explored by the current studies, including most long-chain PFAS (e.g., PFTrDA, PFTeDA) as well as short-chain congeners and functionalized perfluoropolyether as substitutes (e.g., chlorinated poly-fluoroalkyl ether sulfonic acids (Cl-PFESAs) or F-53B with China as the sole source of emissions (121), with some data coming from numerical processing of images as well as from formula conversion. Additionally, different data types (continuous vs. categorical exposure, log-transformed vs. untransformed) are not sufficiently grouped for a meta-analysis. Second, the generalizability of the study results was relatively inadequate. We must take into account that the type and prevalence of different birth outcomes are closely related to the level of public health prevention and control as well as the economy and socio-cultural environment of the area where pregnant women live. However, the majority of the included studies (34/46) were from developed countries/regions, which limits the generalizability of the findings. Third, the possibility of unknown or unmeasured confounders cannot be excluded from our summary effect estimates. Although potential confounders were controlled by the included studies, some important confounders, such as maternal age and GFR, were controlled in only a few of the included studies. Finally, the limited data that could be extracted from the included studies prohibited us from further analyzing the differences in maternal age and GFR, although we performed subgroup analyses to the extent possible. Given the limited amount of evidence observed, future studies should aim to elucidate the association between birth outcome indicators and PFAS exposure in terms of dose and causality.

CONCLUSIONS
Our study showed that PFAS exposure was significantly associated with an increased risk of multiple adverse birth outcomes. Specifically, PFOS, PFPA, PFHxS, PFNA, PFUnDA, PFHpS, and PFOA exposures were negatively associated with BW; PFOA and PFOS exposures were negatively associated with BL and PI; PFOS and PFOA exposures were negatively associated with HC; PFHpS exposure was negatively associated with GA, and PFNA and PFHpS exposures were positively associated with PTB risk. Additionally, PFOA exposure was positively associated with risk of SGA. Further epidemiological studies, especially with cohort study designs, are needed to expand the sample size to further elaborate the effects of different types and doses of PFAS exposure on birth outcomes, which is essential to verify the causality and dose-response curves. In addition, future studies should use mediation analysis and fully consider residual confounders.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS
S-YG and Y-NC conceived the idea, performed the statistical analysis, and drafted this meta-analysis. K-JW, WL, and W-JW selected and retrieved relevant papers. H-RL, S-YG, and Y-NC assessed each study. C-YH and Z-XJ was the guarantor of the analysis, and drafted this meta-analysis. K-JW, WL, and W-JW S-YG and Y-NC conceived the idea, performed the statistical analysis, and drafted this meta-analysis. K-JW, WL, and W-JW

FUNDING
This study was supported by Key Projects of Natural Science Research of Anhui Provincial Department of Education (KJ2020A0163) and National Natural Science Foundation of China (82070986).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.855348/full#supplementary-material

REFERENCES
1. Abbott BD, Wolf CJ, Schmid JE, Das KP, Zehr RD, Helfant L, et al. Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha. Toxicol Sci. (2007) 98:571–81. doi: 10.1093/toxsci/kfm110
2. Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Tully JS, Needham LL. Serum concentrations of 11 polyfluoroalkyl compounds in the u.s. population: data from the national health and nutrition examination survey (NHANES). Environ Sci Technol. (2007) 41:2237–42. doi: 10.1021/es062686m
3. Sina MW, Jaffé PR. A critical review of modeling Poly- and Perfluoroalkyl Substances (PFAS) in the soil-water environment. Sci Total Environ. (2021) 757:143793. doi: 10.1016/j.scitotenv.2020.143793
18. Song X, Jiang L, Wang S, Tian J, Yang K, Wang X, et al. The impact of main air
20. Souza MCO, Saraiva MCP, Honda M, Barbieri MA, Bettiol H, Barbosa F, et al. Exposure to per- and polyfluorinated alkyl substances in pregnant
21. Wang S, Hu C, Li A, Wang Y, Cao L, Wu W, et al. Association between prenatal exposure to persistent organic pollutants and neurodevelopment in early life: a mother-child cohort (Shanghai, China). *Ecotoxicol Environ Saf.* (2021) 208:111479. doi: 10.1016/j.ecosy.2021.111479

22. Chang ET, Adami HO, Boffetta P, Cole P, Starr TB, Mandel JS. A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and cancer risk in humans. *Crit Rev Toxicol.* (2014) 44:1–81. doi: 10.3109/10408444.2014.905767

23. Chang ET, Adami HO, Boffetta P, Wedner HJ, Mandel JS. A critical review of perfluorooctanoic and perfluorooctanesulfonate exposure and immunological health conditions in humans. *Crit Rev Toxicol.* (2016) 46:279–331. doi: 10.1080/10408444.2015.1122573

24. Bach C, Dauchy X, Boiteux V, Colin A, Hemard J, Sagres V, et al. The impact of two fluoropolymer manufacturing facilities on downstream contamination of a river and drinking water resources with per- and polyfluoralkyl substances. *Environ Sci Pollut Res Int.* (2017) 24:4916–25. doi: 10.1007/s11356-016-8243-3

25. Conway BN, Badders AN, Costacou K, Arthur JM, Innes KE. Perfluoralkyl substances and kidney function in chronic kidney disease, anemia, and diabetes. *Diabetes Metab Syndr Obes.* (2018) 11:707–16. doi: 10.2147/DMSO.S90228

26. Kim MJ, Moon S, Oh BC, Jung D, Ji K, Choi K, et al. Association between perfluoralkyl substances exposure and thyroid function in adults: a meta-analysis. *PloS One.* (2018) 13:e0197244. doi: 10.1371/journal.pone.0197244

27. Lewis RC, Johns LE, Meeker JD. Serum biomarkers of exposure to perfluoralkyl substances in relation to serum testosterone and measures of thyroid function among adults and adolescents from NHANES 2011-2012. Int J Environ Res Public Health. (2015) 12:6098–114. doi: 10.3390/ijerph12106098

28. Christensen KY, Raymond M, Meiman J. Perfluoralkyl substances and metabolic syndrome. Int J Hygiene Environ Health. (2019) 222:147–53. doi: 10.1016/j.ijheh.2018.08.014

29. Hjermtislev MH, Long M, Wieloe R, Bonefeld-Jørgensen EC. Persistent organic pollutants in Greenland pregnant women and indices of foetal growth: The ACEPT study. *Sci Total Environ.* (2020) 698:134118. doi: 10.1016/j.scitotenv.2019.134118

30. Rovira J, Martinez M, Sharma RP, Espus T, Nadal M, Kumar V, et al. Prenatal exposure to PFOS and PFOA in a pregnant women cohort of Catalonia, Spain. *Environ Res.* (2019) 175:384–392. doi: 10.1016/j.envres.2019.05.040

31. Wu M, Sun R, Wang M, Liang H, Ma S, Han T, et al. Analysis of perfluorinated compounds in human serum from the general population in Shanghai by liquid chromatography-tandem mass spectrometry (LC-MS/MS). *Chemosphere.* (2017) 168:100–5. doi: 10.1016/j.chemosphere.2016.09.161

32. Liu CY, Chen PC, Lien PC, Liao YP. Prenatal Perfluorooctyl sulfonate exposure and alu DNA hypomethylation in cord blood. *Int J Environ Res Public Health.* (2018) 15:6. doi: 10.3390/ijerph15061066

33. Benninghoff AD, Bisson WH, Koch DC, Ehresman DJ, Kolluri SK, Williams DJ, Estrogen-like activity of perfluoralkyl acids in vivo and interaction with human and rainbow trout estrogen receptors in vitro. *Toxicol Sci.* (2011) 120:42–58. doi: 10.1093/toxsci/kfq379

34. Kjeldsen LS, Bonefeld-Jørgensen EC. Perfluorinated compounds affect the function of sex hormone receptors. *Toxicology.* (2011) 117:707–16. doi: 10.2147/DMSO.S173809

35. Lopez-Espinosa MJ, Mondal D, Armstrong BG, Eskenazi B, Fletcher T. Perfluoroalkyl substances exposure and thyroid function in adults: a meta-analysis. *Int J Hygiene Environ Health.* (2018) 222:147–53. doi: 10.1016/j.ijheh.2018.08.014

36. Marks KJ, Cutler AJ, Jeddy Z, Northstone K, Kato K, Hartman TJ. Longitudinal cohort with repeated measurements. *Environ Res.* (2017) 159:95–102. doi: 10.1016/j.envres.2017.07.050

37. Christensen KY, Raymon M, Meiman J. Perfluoralkyl substances and thyroid function. *Environ Sci Technol.* (2017) 51:128899. doi: 10.1021/acs.est.7b03575

38. Knudsen AL, Røgalement-Reidt M, Esbsen S, Christiansen K, Brøndsted J, Hansen J. Perfluorinated substances in umbilical cord serum and gestational age at 6-9 years of age: a cross-sectional analysis within the c8 health project. *Toxicol Sci.* (2018) 168:100–5. doi: 10.1016/j.chemosphere.2019.134118

39. Kjeldsen LS, Bonefeld-Jørgensen EC. Perfluorinated compounds affect the function of sex hormone receptors. *Toxicology.* (2011) 117:707–16. doi: 10.2147/DMSO.S173809

40. Caldeirão-Garcidueñas L, Torres-Jardón R, Kulesza RJ, Mansour Y, González-González LO, González-Maciel A, et al. Alzheimer disease starts in childhood in polluted Metropolitan Mexico City, a major health crisis in progress. *Environ Res.* (2020) 183:109137. doi: 10.1016/j.envres.2020.109137

41. McGuinn LA, Bellinger DC, Colicino E, Coubal BA, Just AC, Klop I, et al. Prenatal PM(2.5) exposure and behavioral development in children from Mexico City. *Neurotoxicology.* (2020) 81:109–115. doi: 10.1016/j.neuro.2020.09.036

42. Li M, Tang J, Yang H, Zhao L, Liu Y, Xu H, et al. Short-term exposure to ambient particulate matter and outpatient visits for respiratory diseases among children: a time-series study in five Chinese cities. *Chemosphere.* (2021) 263:128214. doi: 10.1016/j.chemosphere.2021.128214

43. Song X, Jiang L, Wang S, Tian J, Yang K, Wang X, et al. The impact of main air pollutants on respiratory emergency department visits and the modification effects of temperature in Beijing, China. *Environ Sci Pollut Res Int.* (2021) 28:6990–7000. doi: 10.1007/s11356-020-10949-z

44. Souza MCO, Saraiva MCP, Honda M, Barbieri MA, Bettiol H, Barbosa F, et al. Exposure to per- and polyfluorinated alkyl substances in pregnant Brazilian women and its association with fetal growth. *Environ Res.* (2020) 187:109585. doi: 10.1016/j.envres.2020.109585

45. Wang S, Hu C, Li A, Wang Y, Cao L, Wu W, et al. Association between prenatal exposure to persistent organic pollutants and neurodevelopment in early life: a mother-child cohort (Shanghai, China). *Ecotoxicol Environ Saf.* (2021) 208:111479. doi: 10.1016/j.ecosy.2021.111479
pollutants and birth size: the LIFE study. *Environ Health Perspect.* (2015) 123:88–94. doi: 10.1289/ehp.1308016

40. Wang Y, Adgent M, Su PH, Chen HJ, Chen PC, Hsuing CA, et al. Prenatal exposure to perfluorocarboxylic acids (PFCSAs) and fetal and postnatal growth in the Taiwan maternal and infant cohort study. *Environ Health Perspect.* (2016) 124:1794–800. doi: 10.1289/ehp.1509998

41. Ashley-Martin J, Dodds L, Arbuckle TE, Bouchard ME, Fisher M, Morriseyt AS, et al. Maternal concentrations of perfluoralkyl substances and fetal markers of metabolic function and birth weight. *American journal of epidemiology.* (2017) 185:185–93. doi: 10.1093/aje/kww213

42. Lee YJ, Kim MK, Bae J, Yang JH. Concentrations of perfluoralkyl compounds in maternal and umbilical cord sera and birth outcomes in Korea. *Chemosphere.* (2013) 96:1603–9. doi: 10.1016/j.chemosphere.2012.08.035

43. Fei C, McLaughlin JK, Tarone RE, Olsen J. Fetal growth indicators and perfluorinated chemicals: a study in the Danish National Birth Cohort. *Am J Epidemiol.* (2008) 168:66–72. doi: 10.1093/aje/kwn095

44. Maisonet M, Terrell ML, McGeehin MA, Christensen KY, Holmes A, Calafat AM, et al. Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. *Environ Health Perspect.* (2012) 120:1432–7. doi: 10.1289/ehp.103096

45. Lenters V, Portengen L, Rignell-Hydbom A, Jonsson BA, Lindh CH, Piersma AH, et al. Prenatal phthalate, perfluoralkyl acid, and organochlorine exposures and term birth weight in three birth cohorts: multi-pollutant models based on elastic net regression. *Environ Health Perspect.* (2016) 124:365–72. doi: 10.1289/ehp.1408933

46. Eick SM, Hom Thepaksorn EK, Izano MA, Cushing LJ, Wang Y, Negri E, Metruccio F, Guercio V, Tosti L, Benfenati E, Bonzi R, et al. Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth: a study within the Danish National Birth Cohort. *Environ Health Perspect.* (2017) 125:185–93. doi: 10.1289/ehp.150213

47. Steenland K, Barry V, Savitz D. Serum perfluorooctanoic acid and markers of metabolic function and birth weight. *Environ Health Perspect.* (2016) 124:848–54. doi: 10.1289/ehp.1510046

48. Evangeline L, Nitritos G, Chondrogiorghi M, Kavourouka FK, Hernández AF, Ntzani EE, et al. Exposure to pesticides and diabetes: A systematic review and meta-analysis. *Int J Epidemiol.* (2016) 45:610–8. doi: 10.1093/ije/dyw210

49. Taylor KW, Novak RF, Anderson HA, Birnbaum LS, Blystone C, Devito M, et al. Evaluation of the association between persistent organic pollutants (POPs) and diabetes in epidemiological studies: a national toxicology program workshop review. *Environ Health Perspect.* (2013) 121:774–83. doi: 10.1289/ehp.1205502

50. Fei C, McLaughlin JK, Tarone RE, Olsen J. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. *Environ Health Perspect.* (2007) 115:1677–82. doi: 10.1289/ehp.10506

51. Chen MH, Ng S, Hsieh CJ, Lin CC, Hsieh HS, Chen PC. The impact of prenatal perfluoralkyl substances exposure on neonatal and child growth. *Sci Total Environ.* (2017) 607–610. doi: 10.1016/j.scitotenv.2016.08.123

52. Chen MH, Ha EH, Wen TW, Su YN, Lien GW, Chen CY, et al. Perfluorinated compounds in umbilical cord blood and adverse birth outcomes. *PloS One.* (2017) 12:e0184274. doi: 10.1371/journal.pone.0184274

53. Lauritzen HB, Larose TL, Olsen T, Sandanger TM, Oldland J, van de Bor M, Jacobsen GW. Maternal serum levels of perfluoroalkyl substances and organochlorines and indices of fetal growth: a Scandinavian case-cohort study. *Pediatr Res.* (2017) 81:33–42. doi: 10.1038/pr.2016.187

54. Bjerregaard-Olesen C, Bach CC, Long M, Wielsøe M, Bech BH, Henriksen TB, et al. Associations of fetal growth outcomes with measures of the combined xenobiotic exposure of maternal serum perfluorinated alkyl acids in Danish pregnant women. *Environ Health Perspect.* (2019) 127:17006. doi: 10.1289/EHP1884

55. Li M, Zeng KW, Qian ZM, Vaughan MG, Sauvé S, Paul G, et al. Isomers of perfluorooctanesulfonate (PFOS) in cord serum and birth outcomes in China: Guangzhou Birth Cohort Study. *Environ Int.* (2017) 102:1–8. doi: 10.1016/j.envint.2017.03.006

56. Manzano-Salgado CB, Casas M, Lopez-Espinosa MJ, Ballester F, Iñiguez C, Martínez D, et al. Prenatal exposure to perfluoralkyl substances and birth outcomes in a Spanish birth cohort. *Environ Int.* (2017) 108:278–84. doi: 10.1016/j.envint.2017.09.006

57. Valvi D, Oulhote Y, Weihe P, Dalgaard C, Bjerve KS, Steuerwald U, et al. Gestational diabetes and offspring birth size at elevated environmental pollutant exposures. *Environ Int.* (2017) 107:205–15. doi: 10.1016/j.envint.2017.07.016

58. Sagiv SK, Rifas-Shiman SL, Fleisch AF, Webster TF, Calafat AM, Ye X, et al. Early-pregnancy plasma concentrations of perfluoralkyl substances and birth outcomes in project vivica: confounded by pregnancy hemodynamics? Am J Epidemiol. (2018) 187:793–802. doi: 10.1093/aje/kwx332

59. Premaratne S, Newman J, Hobbs S, Garnham A, Wall M. Meta-analysis of direct surgical vs. endovascular revascularization for aortoiliac occlusive disease. *J Vasc Surg.* (2020) 72:726–37. doi: 10.1016/j.jvs.2019.12.035

60. Brots AG, Churis I, Karvouniaris M. Local complications of adjunct intrathecal antibiotics for nosocomial meningitis associated with gram-negative pathogens: a meta-analysis. *Neurosur Rev.* (2021) 44:139–52. doi: 10.1007/s10314-019-01226-w

61. Hamm MP, Cherry NM, Chan E, Martin JW, Burstyn I. Maternal exposure to perfluorinated acids and fetal growth. *J Exposure Sci Environ Epidemiol.* (2010) 20:589–97. doi: 10.1038/jes.2009.57

62. Khreis H, Kelly C, Tate J, Parslow R, Lucas K, Nieuwenhuijsen M, Exposure to traffic-related air pollution and risk of development of childhood asthma: A systematic review and meta-analysis. *Environ Int.* (2017) 100:1–31. doi: 10.1016/j.envint.2016.11.012

63. Green H, Rahimov R, Gafser U, Leibovici L, Paul M. Antibiotic prophylaxis for urinary tract infections in renal transplant recipients: a systematic review and meta-analysis. *Transpl Infect Dis.* (2011) 13:441–7. doi: 10.1111/j.1399-3062.2011.00644.x
Gui et al. Perfluoroalkyl Substances and Birth Outcomes

74. Fan SJ, Heinrich J, Bloom MS, Zhao TY, Shi TX, Feng WR, et al. Ambient air pollution and depression: A systematic review with meta-analysis up to 2019. *Sci Total Environ.* (2020) 701:134721. doi: 10.1016/j.scitotenv.2019.134721

75. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol.* (2011) 64:380–2. doi: 10.1016/j.jclinepi.2010.09.011

76. Apelberg BJ, Witter FR, Herbstman JB, Calafat AM, Halden RU, Needham LL, et al. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) in relation to weight and size at birth. *Environ Health Perspect.* (2007) 115:1670–6. doi: 10.1289/ehp.10334

77. Washino N, Saito Y, Sasaki S, Kato S, Ban S, Konishi K, et al. Correlations between prenatal exposure to perfluorinated chemicals and reduced fetal growth. *Environm Health Perspect.* (2009) 117:660–7. doi: 10.1289/ehp.11681

78. Savitz DA, Stein CR, Elston B, Wellenius GA, Bartell SM, Shin HM, et al. Relationship of perfluorooctanoic acid exposure to pregnancy outcome based on birth records in the mid-Ohio Valley. *Environ Health Perspect.* (2012) 120:1201–7. doi: 10.1289/ehp.1104752

79. Whitworth KW, Haug LS, Baird DD, Becker G, Hoppin JA, Skaerved R, et al. Perfluorinated compounds in relation to birth weight in the Norwegian Mother and Child Cohort Study. *Am J Epidemiol.* (2012) 175:1209–16. doi: 10.1093/aje/kwr439

80. Wu K, Xu X, Peng L, Liu J, Guo Y, Huo X. Association between maternal exposure to perfluorooctanoic acid (PFOA) from electronic waste recycling and neonatal health outcomes. *Environ Int.* (2012) 48:1–7. doi: 10.1016/j.envint.2012.06.018

81. Darrow LA, Stein CR, Steenland K. Serum perfluorooctanoic acid and perfluorooctane sulfonate concentrations in relation to birth outcomes in the Mid-Ohio Valley, 2005–2010. *Environ Health Perspect.* (2013) 121:1207–13. doi: 10.1289/ehp.1206372

82. Alkhalawi E, Kasper-Sonnenberg M, Wilhelm M, Völkel W, Wittsiepe J. Perfluoralkyl acids (PFAAs) and anthropometric measures in the first year of life: Results from the Duisburg Birth Cohort. *J Toxicol Environ Health A.* (2016) 79:1041–49. doi: 10.1080/1556976X.2016.1219552

83. Callan AC, Rotander A, Thompson K, Heyworth J, Mueller JE, Olund J, et al. Maternal exposure to perfluoralkyl acids measured in whole blood and birth outcomes in *Sci Total Environ.* (2016) 569:57–61. doi: 10.1016/j.scitotenv.2016.06.177

84. Kwon EJ, Shin JS, Kim BM, Shah-Kulkarni S, Park H, Kho YL, et al. Prenatal exposure to perfluorinated compounds affects birth weight and adiposity at birth: examining mediation by maternal fasting glucose in the healthy start study. *Environ Health Perspect.* (2013) 121:63–9. doi: 10.1289/ehp.1104753

85. Liu X, Chen D, Wang B, Xu F, Pang Y, Zhang L, et al. Does low maternal exposure to per- and polyfluoralkyl substances elevate the risk of spontaneous preterm birth? A nested case-control study in China. *Environ Sci Technol.* (2020) 54:8259–68. doi: 10.1021/acs.est.0c01930

86. Lind DV, Priskorn L, Lassen TH, Nielsen F, Kyhl HB, Kristensen DM, et al. Prenatal exposure to perfluoralkyl substances and anogenital distance at 3 months of age in a Danish mother-child cohort. *Reprod Toxicol.* (2017) 68:202–6. doi: 10.1016/j.reprotox.2016.08.019

87. Arzouk TE, MacPherson S, Foster WG, Sathyarayana S, Fisher M, Monnier P, et al. Prenatal perfluoroalkyl substances and newborn anogenital distance in a Canadian cohort. *Reprod Toxicol.* (2020) 94:31–9. doi: 10.1016/j.reprotox.2020.03.011

88. Nolans LA, Nolan JM, Shofrer FS, Rodway NV, Emmett EA. The relationship between birth weight, gestational age and perfluorooctanoic acid (PFOA)-contaminated public drinking water. *Reprod Toxicol.* (2009) 27:231–8. doi: 10.1016/j.reprotox.2008.11.001

89. Nolans LA, Nolan JM, Shofrer FS, Rodway NV, Emmett EA. Congenital anomalies, labor/delivery complications, maternal risk factors and their relationship with perfluorooctanoic acid (PFOA)-contaminated public drinking water. *Reprod Toxicol.* (2010) 29:147–55. doi: 10.1016/j.reprotox.2009.10.012

90. Manea S, Salmaso L, Lorenzoni G, Mazzucato M, Russo F, Mantoan D, et al. Exposure to PFAS and small for gestational age newborns: a birth records study in Veneto Region (Italy). *Environ Res.* (2020) 184:109282. doi: 10.1016/j.envres.2020.10.9282

91. Savitz DA, Stein CR, Bartell SM, Elston B, Gong J, Shin HM, et al. Perfluorooctanoic acid exposure and pregnancy outcome in a highly exposed community. *Epidemiology.* (2012) 23:386–92. doi: 10.1097/EDE.0b013e31824cb93b

92. Darrow LA, Alkhalawi E, Takens LA, Vestergaard A, Steenland K. PFOA and PFOS serum levels and miscarriage risk. *Epidemiology.* (2014) 25:505–12. doi: 10.1097/EDE.0000000000001033

93. Louis GM, Sapra KJ, Barr DB, Lu Z, Sundaram R. Preconception perfluoralkyl and polyfluoroalkyl substances and incident pregnancy loss, *LIFE Study. Reprod Toxicol.* (2016) 65:11–17. doi: 10.1016/j.reprotox.2016.06.011

94. Stein CR, Savitz DA, Dougan M. Serum levels of perfluorooctanoic acid and perfluorooctane sulfonate and pregnancy outcome. *Am J Epidemiol.* (2009) 170:837–46. doi: 10.1093/aje/kwp212

95. Jensen TK, Andersen LB, Kyhl HB, Nielsen F, Christesen HT, Grandjean P. Association between perfluorinated compound exposure and miscarriage in Danish pregnant women. *PloS one.* (2015) 10.e0123496. doi: 10.1371/journal.pone.0123496

96. Liew Z, Luo J, Nohr EA, Bech BH, Bossi R, Arah OA, et al. Maternal plasma perfluoralkyl substances and miscarriage in Danish pregnant women. *PloS one.* (2015) 10.e0123496. doi: 10.1371/journal.pone.0123496

97. Kishi R, Nakajima T, Goudarzi H, Kobayashi S, Sasaki S, Okada E, et al. Maternal perfluorinated exposure to perfluorinated chemicals with maternal essential and long-chain polyunsaturated fatty acids during pregnancy and the birth weight of their offspring: the Hokkaido Study. *Environ Health Perspect.* (2015) 123:1038–45. doi: 10.1289/ehp.1408834
Fromme H, Mosch C, Morovitz M, Alba-Alejandre I, Boehmer S, Kiranoglu M, Et al. Pre- and postnatal exposure to perfluorinated compounds (PFCs). Environ Sci Technol. (2010) 44:7123–9. doi: 10.1021/es101184f

Gentry PR, Covington TR, Andersen ME, Clewell HJ. Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul Toxicoll Pharmacol. (2002) 36:51–68. doi: 10.1006/rtph.2002.1540

Kato K, Wong LY, Chen A, Dunbar C, Webster GM, Lanphear BP, Et al. Changes in serum concentrations of maternal poly- and perfluoroalkyl substances over the course of pregnancy and predictors of exposure in a multiethnic cohort of Cincinnati, Ohio pregnant women during 2003-2006. Environ Sci Technol. (2014) 48:9600–8. doi: 10.1021/es501811k

Verner MA, Lociansano AE, Morken NH, Yoon M, Wu H, McDougall R, Et al. Associations of perfluoroalkyl substances (PFAS) with lower birth weight: an evaluation of potential confounding by glomerular filtration rate using a physiologically based pharmacokinetic model (PBPK). Environ Health Perspect. (2015) 123:1317–24. doi: 10.1289/ehp.1408837

Winquist A, Steenland K. Modeled PFOA exposure and lifetime cancer risk to workers at a Washington State chemical manufacturing company. Environ Health Perspect. (2014) 122:1299–305. doi: 10.1289/ehp.1307943

Vanden Heuvel JP, Thompson JT, Frame SR, Gilles PJ. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci. (2006) 92:476–89. doi: 10.1093/toxsci/kfl014

Hines EP, White SS, Stanko JP, Gibbs-Flourny EA, Lau C, Fenton SE. Phenotypic dichotomy following developmental exposure to perfluorooctanoic acid (PFOA) in female CD-1 mice: Low doses induce elevated serum leptin and insulin, and overweight in mid-life. Mol Cell Endocrinol. (2009) 304:97–105. doi: 10.1016/j.mce.2009.02.021

Wan HT, Zhao YG, Leung PY, Wong CK. Perinatal exposure to perfluoroctane sulfate affects glucose metabolism in adult offspring. PloS One. (2014) 9:e87157. doi: 10.1371/journal.pone.0087137

Goudarzi H, Araki A, Itoh S, Sasaki S, Miyashita C, Mitsu T, Et al. The association of prenatal exposure to perfluorinated chemicals with glucocorticoid and androgenic hormones in cord blood samples: the Hokkaido Study. Environ Health Perspect. (2017) 125:111–118. doi: 10.1289/EHP142

Fletcher T, Galloway TS, Melzer D, Holcroft P, Cipelli R, Pilling LC, Et al. Associations between PFOA, PFOS and changes in the expression of genes involved in cholesterol metabolism in humans. Environ Int. (2013) 57-58:2–10. doi: 10.1016/j.envint.2013.03.008

Bjerregaard-Olesen C, Bach CC, Long M, Ghisari M, Bech BH, Nohr EA, Et al. Determinants of serum levels of perfluorinated alkyl acids in Danish pregnant women. Int J Hygiene Environ Health. (2016) 219:867–75. doi: 10.1016/j.ijeh.2016.07.008

Shi Y, Vestergren R, Xu L, Zhou Z, Li C, Liang Y, Et al. Human exposure and elimination kinetics of chlorinated polyfluoralkyl ether sulfonic acids (CI-PFESAs). Environ Sci Technol. (2016) 50:2396–404. doi: 10.1021/acs.est.5b05849

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Gui, Chen, Wu, Liu, Wang, Liang, Jiang, Li and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.